[go: up one dir, main page]

BR9710372A - Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase - Google Patents

Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase

Info

Publication number
BR9710372A
BR9710372A BR9710372A BR9710372A BR9710372A BR 9710372 A BR9710372 A BR 9710372A BR 9710372 A BR9710372 A BR 9710372A BR 9710372 A BR9710372 A BR 9710372A BR 9710372 A BR9710372 A BR 9710372A
Authority
BR
Brazil
Prior art keywords
cliclooxygenase
processes
treatment
pharmaceutical composition
inflammatory disease
Prior art date
Application number
BR9710372A
Other languages
English (en)
Other versions
BRPI9710372B8 (pt
BR9710372B1 (pt
Inventor
Daniel Dube
Rejen Fortin
Richard Friesen
Zhaoyin Wang
Jacques Yves Gauthier
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9710372(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9616126.0A external-priority patent/GB9616126D0/en
Priority claimed from GBGB9621420.0A external-priority patent/GB9621420D0/en
Priority claimed from GBGB9709291.0A external-priority patent/GB9709291D0/en
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of BR9710372A publication Critical patent/BR9710372A/pt
Publication of BR9710372B1 publication Critical patent/BR9710372B1/pt
Publication of BRPI9710372B8 publication Critical patent/BRPI9710372B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
BRPI9710372A 1996-07-18 1997-07-08 composto, e, composição farmacêutica. BRPI9710372B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2212896P 1996-07-18 1996-07-18
GBGB9616126.0A GB9616126D0 (en) 1996-08-01 1996-08-01 Substituted pyridines as selective cyclooxygenase-2 inhibitors
US2713996P 1996-10-01 1996-10-01
GBGB9621420.0A GB9621420D0 (en) 1996-10-15 1996-10-15 Substituted pyridines as selective cyclooxygenase-2 inhibitors
US4181497P 1997-04-08 1997-04-08
GBGB9709291.0A GB9709291D0 (en) 1997-05-07 1997-05-07 Substituted pyridines as selective cyclooxygenase-2 inhibitors
PCT/CA1997/000486 WO1998003484A1 (en) 1996-07-18 1997-07-08 Substituted pyridines as selective cyclooxygenase-2 inhibitors

Publications (3)

Publication Number Publication Date
BR9710372A true BR9710372A (pt) 1999-08-17
BR9710372B1 BR9710372B1 (pt) 2013-02-05
BRPI9710372B8 BRPI9710372B8 (pt) 2021-05-25

Family

ID=27547268

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9710372A BRPI9710372B8 (pt) 1996-07-18 1997-07-08 composto, e, composição farmacêutica.

Country Status (36)

Country Link
EP (1) EP0912518B1 (pt)
JP (2) JP3251945B2 (pt)
KR (1) KR100371620B1 (pt)
CN (1) CN1152863C (pt)
AR (1) AR012825A1 (pt)
AT (1) ATE249437T1 (pt)
AU (1) AU723179B2 (pt)
BG (1) BG64553B1 (pt)
BR (1) BRPI9710372B8 (pt)
CA (2) CA2260016C (pt)
CO (1) CO4900063A1 (pt)
CY (1) CY2409B1 (pt)
CZ (1) CZ292843B6 (pt)
DE (1) DE69724788T2 (pt)
DK (1) DK0912518T3 (pt)
DZ (1) DZ2268A1 (pt)
EA (1) EA001444B1 (pt)
EE (1) EE03680B1 (pt)
ES (1) ES2205242T3 (pt)
HR (1) HRP970389B1 (pt)
HU (1) HU227732B1 (pt)
ID (1) ID19602A (pt)
IL (1) IL127441A (pt)
IS (1) IS1958B (pt)
MY (1) MY134841A (pt)
NO (1) NO313327B1 (pt)
NZ (1) NZ333230A (pt)
PE (1) PE27299A1 (pt)
PL (1) PL187848B1 (pt)
PT (1) PT912518E (pt)
RS (1) RS49881B (pt)
SI (1) SI0912518T1 (pt)
SK (1) SK283261B6 (pt)
TR (1) TR199900046T2 (pt)
TW (1) TW453994B (pt)
WO (1) WO1998003484A1 (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
EP0975604B1 (en) * 1997-03-14 2004-07-21 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
TW492959B (en) * 1997-04-18 2002-07-01 Merck & Co Inc Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
US6130334A (en) * 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6127545A (en) * 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
PT1042293E (pt) * 1997-12-19 2008-04-18 Amgen Inc Compostos de piridazina e piridina substituídos e as suas utilizações farmacêuticas
US6174901B1 (en) * 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
JP2001526230A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
JP2002506024A (ja) * 1998-03-13 2002-02-26 メルク エンド カムパニー インコーポレーテッド 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
ES2226378T3 (es) * 1998-04-24 2005-03-16 MERCK & CO., INC. Procedimiento para la sintesis de inhibidores de cox-2.
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002523461A (ja) * 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 神経変性疾患の治療方法
ATE258055T1 (de) 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6350744B1 (en) * 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1140083A4 (en) 1999-01-08 2004-01-02 Smithkline Beecham Corp NEW CONNECTIONS
KR100446324B1 (ko) 1999-01-14 2004-08-30 론자 아게 1-(6-메틸피리딘-3-일)-2-[4-(메틸술포닐)페닐]에타논 및이의 제조 방법
DE50009312D1 (de) * 1999-01-14 2005-02-24 Lonza Ag Verfahren zur Herstellung von 1-(6-Methylpyridin-3-yl)-2-[4-(methylsulfonyl)-phenyl]ethanon
US6566527B1 (en) 1999-07-27 2003-05-20 Merck & Co., Inc. Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-methylsulphonyl)-phenyl]ethanone
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
AU776544B2 (en) 1999-11-29 2004-09-16 Merck Canada Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-(2,3') bipyridinyl
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
US6924303B2 (en) 2000-06-13 2005-08-02 Wyeth Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
JP2004517870A (ja) * 2001-01-02 2004-06-17 藤沢薬品工業株式会社 シクロオキシゲナーゼ阻害剤
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
GB0112803D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112802D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
GB0119477D0 (en) 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
EP2298759A1 (en) 2002-08-30 2011-03-23 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP2196201A3 (en) 2002-12-13 2010-12-08 Warner-Lambert Company LLC Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214130B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 2-3'-bipiridinas.
DE602004002832T2 (de) 2003-05-07 2007-06-06 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
DE10322844A1 (de) * 2003-05-19 2004-12-16 Clariant Gmbh Verfahren zur Herstellung von Pyridin-2-boronsäureestern
JP2008525363A (ja) 2004-12-23 2008-07-17 グラクソ グループ リミテッド プロスタグランジン媒介疾患治療のためのピリジン化合物
JP2006306743A (ja) * 2005-04-26 2006-11-09 Hamamatsu Photonics Kk 体液処理方法
GEP20115226B (en) 2005-04-26 2011-06-10 Pfizer P-cadherin antibodies
SI1933871T1 (sl) 2005-09-07 2013-10-30 Amgen Fremont Inc. Humana monoklonska protitelesa proti aktivin receptorju podobni kinazi-1
US20080153888A1 (en) 2006-12-22 2008-06-26 Recordati Ireland Limited Alpha-2-delta ligand/nsaid therapeutic treatment of lower urinary tract disorders
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
WO2010097802A2 (en) 2009-02-27 2010-09-02 Cadila Healthcare Limited A process for the preparation of etoricoxib
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
WO2012004677A1 (en) * 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
EP2590953B1 (en) 2010-07-09 2014-10-29 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
ES2541416T3 (es) 2011-01-19 2015-07-20 Convergence Pharmaceuticals Limited Derivados de piperazina como bloqueadores de los canales de calcio Cav2.2
EA023286B1 (ru) 2011-05-27 2016-05-31 ФАРМА ДжРС, Д.О.О. Способ получения полиморфной формы i эторикоксиба
CN102952117B (zh) * 2011-08-25 2014-11-26 青岛欧博方医药科技有限公司 咪唑衍生物的制备方法
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN104788362A (zh) * 2014-01-21 2015-07-22 济南三元化工有限公司 一种依托考昔或其药学上可接受的盐的制备方法
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
WO2016149126A1 (en) 2015-03-13 2016-09-22 The Board Of Trustees Of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
WO2018049008A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Dash inhibitors, and uses related thereto
CN106632002A (zh) * 2016-09-28 2017-05-10 贵州大学 一种依托考昔及其对照品5‑氯‑3‑(4‑(甲基磺酰基)苯基)‑2,3‑联吡啶的制备工艺
CN107056781A (zh) * 2017-05-18 2017-08-18 康化（上海）新药研发有限公司 一种(E)‑5‑甲基‑1H‑吡咯并[2,3‑b]吡啶‑3‑甲醛肟的合成方法
CN107286085B (zh) * 2017-05-25 2020-06-16 华东师范大学 一种吡啶类衍生物及其合成方法
CN107556232A (zh) * 2017-09-26 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与盐酸形成盐的新晶型及制备方法
AR113270A1 (es) 2017-10-04 2020-03-11 Japan Tobacco Inc Compuesto de heteroarilo con contenido de nitrógeno y su uso farmacéutico
CN110041253B (zh) * 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
KR102257685B1 (ko) * 2018-09-20 2021-05-31 성균관대학교산학협력단 Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물
CN109432409A (zh) * 2018-12-19 2019-03-08 上海康孕企业管理合伙企业（有限合伙） 血红素在改善痛经的药物、食品及保健食品中的应用
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
CN115806521B (zh) * 2021-09-15 2025-04-18 华东理工大学 一种单氟甲基依托昔布及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation

Also Published As

Publication number Publication date
PL330995A1 (en) 1999-06-21
CA2412968A1 (en) 1998-01-29
PL187848B1 (pl) 2004-10-29
EA001444B1 (ru) 2001-04-23
NO990191D0 (no) 1999-01-15
IS4927A (is) 1998-12-18
ATE249437T1 (de) 2003-09-15
SI0912518T1 (en) 2003-12-31
EA199900137A1 (ru) 1999-06-24
JPH11514008A (ja) 1999-11-30
JP3251945B2 (ja) 2002-01-28
HRP970389A2 (en) 1998-06-30
KR100371620B1 (ko) 2003-05-09
JP4246930B2 (ja) 2009-04-02
DE69724788D1 (en) 2003-10-16
CA2412968C (en) 2010-05-11
EP0912518A1 (en) 1999-05-06
RS49881B (sr) 2008-08-07
KR20000067891A (ko) 2000-11-25
IL127441A0 (en) 1999-10-28
TR199900046T2 (xx) 1999-04-21
EP0912518B1 (en) 2003-09-10
HK1023767A1 (en) 2000-09-22
DZ2268A1 (fr) 2002-12-25
BRPI9710372B8 (pt) 2021-05-25
CZ292843B6 (cs) 2003-12-17
IS1958B (is) 2004-11-15
AR012825A1 (es) 2000-11-22
EE9900018A (et) 1999-08-16
CY2409B1 (en) 2004-09-10
HRP970389B1 (en) 2002-10-31
HUP9903974A3 (en) 2001-12-28
HUP9903974A2 (hu) 2000-03-28
TW453994B (en) 2001-09-11
IL127441A (en) 2003-02-12
ES2205242T3 (es) 2004-05-01
DE69724788T2 (de) 2004-08-05
CA2260016A1 (en) 1998-01-29
JP2002080453A (ja) 2002-03-19
ID19602A (id) 1998-07-23
NO990191L (no) 1999-03-16
PE27299A1 (es) 1999-03-12
CZ13099A3 (cs) 1999-06-16
PT912518E (pt) 2003-12-31
BG64553B1 (bg) 2005-07-29
AU3331997A (en) 1998-02-10
WO1998003484A1 (en) 1998-01-29
EE03680B1 (et) 2002-04-15
SK283261B6 (sk) 2003-04-01
BR9710372B1 (pt) 2013-02-05
BG103179A (en) 1999-11-30
CN1152863C (zh) 2004-06-09
MY134841A (en) 2007-12-31
CO4900063A1 (es) 2000-03-27
DK0912518T3 (da) 2003-12-08
NO313327B1 (no) 2002-09-16
NZ333230A (en) 2000-08-25
HU227732B1 (en) 2012-01-30
CN1225085A (zh) 1999-08-04
SK3699A3 (en) 1999-12-10
AU723179B2 (en) 2000-08-17
CA2260016C (en) 2004-03-09
YU59198A (sh) 2001-07-10

Similar Documents

Publication Publication Date Title
BR9710372A (pt) Composto composi-Æo farmac-utica e processos para o tratamento de uma doen-a inflamatÄria e de doen-as mediadas pela cliclooxigenase
PT966436E (pt) Arilsulfonamidas e analogos e sua aplicacao para o tratamento de doencas neurodegenerativas
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
PT977748E (pt) Derivados benzopirano substituidos para o tratamento de inflamacao
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
FI20115753L (fi) Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
FI933770A7 (fi) Farmaseuttisia koostumuksia ihotautien hoitamiseen
KR100344712B1 (ko) 알러지성및염증성질환의치료에유용한화합물
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
LV11865A (lv) Kompozicijas un panemieni tuklo sunu iekaisumu arstesanai
ITMI950529A0 (it) Composizioni farmaceutiche e procedimento per la loro preparazione
FI962249A7 (fi) Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
FR2722984B1 (fr) Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
HUP0102295A3 (en) Benzamide derivatives for the treatment of diseases mediated by cytokines
DE602004019206D1 (de) Entzündungshemmende arzneizubereitungen zur entzündungsverminderung und die therapie oder die prophylaxe von der gastrischen toxizität
BR9611563A (pt) Composto composição farmacêutica método de tratamento de uma doença inflamatória e ensaio para detectar inibidores de agrecanase
BR9507166A (pt) Conjunto de dentes para tratamento de uma superfície
PT752246E (pt) Kapa-opiatos para doencas inflamatorias dos intestinos
FI933902A7 (fi) Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
GB9720797D0 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
NO20006506D0 (no) Anvendelse av valproinsyreanalog for behandlingen og forebyggelsen av migrene og affektive sykdommer
PT983275E (pt) Novos derivados do triptolido vantajosos para o tratamento de doencas autoimunes
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
HKEG Application refused (deleted)
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B25A Requested transfer of rights approved

Owner name: MERCK FROSST CANADA AND CO. (CA)

Free format text: TRANSFERIDO POR FUSAO DE: MERCK FROSST CANADA INC.

B25A Requested transfer of rights approved

Owner name: MERCK FROSST CANADA LTD (CA)

Free format text: TRANSFERIDO DE: MERCK FROSST CANADA AND CO.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: MERCK FROSST CANADA LTD (CA)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 020120090453-RJ, DE 25/09/2012, E NECESSARIO REAPRESENTAR O DOCUMENTO DE CESSAO DEVIDAMENTE CONSULARIZADO.

B25D Requested change of name of applicant approved
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2013, OBSERVADAS AS CONDICOES LEGAIS.

B25E Requested change of name of applicant rejected
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/1997 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/07/2017